Element Wealth LLC Has $1.22 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Element Wealth LLC reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 8.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 55,529 shares of the company’s stock after selling 5,000 shares during the quarter. Element Wealth LLC’s holdings in Teva Pharmaceutical Industries were worth $1,224,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $50,000. Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. Finally, Farther Finance Advisors LLC raised its position in Teva Pharmaceutical Industries by 273.5% during the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after acquiring an additional 3,323 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.55% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TEVA. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.75 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company’s 50 day moving average is $19.92 and its 200-day moving average is $18.48.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.